Form 4: Nuvectis Pharma Director and 10% Owner Boosts Stake with Significant Stock Purchases

Marlio Charles Mosseri, a Director and 10% owner of Nuvectis Pharma, Inc., has significantly increased his beneficial ownership through recent open market purchases of common stock.

Summary

• Marlio Charles Mosseri, a Director and 10% owner of Nuvectis Pharma, Inc. (NVCT), reported two open market purchases of common stock.
• On June 17, 2025, Mr. Mosseri acquired 5,399 shares of common stock at a price of $8.11 per share.
• On June 18, 2025, an additional 28,043 shares were purchased at a weighted average price of $8.05 per share, with the price range for these transactions being $7.91 to $8.11.
• Following these transactions, Mr. Mosseri's indirect beneficial ownership, held through Emerald Hill Ventures SARL SPF, increased to a total of 2,976,203 shares of common stock.
• Mr. Mosseri is the beneficial owner of Emerald Hill Ventures SARL.

Sentiment

Score: 8

Explanation: The sentiment is positive due to significant insider buying by a director and 10% owner, indicating strong confidence in the company's valuation and future prospects.

Positives

• Significant insider buying by a Director and 10% owner, indicating confidence in the company's future prospects.
• Increased beneficial ownership by a key stakeholder, aligning management and shareholder interests.
• The purchases were made at prices ranging from $7.91 to $8.11, suggesting a belief in value at these levels.

Future Outlook

The Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction; it solely reports recent insider transactions.

Management Comments

• The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

Industry Context

This filing is a standard disclosure of insider trading activity, which is common across all industries for publicly traded companies. It does not provide specific industry-wide trends or competitive analysis.

Comparison to Industry Standards

• This Form 4 filing reports specific insider transactions and does not contain information that allows for a direct comparison to industry-wide financial benchmarks or project results of comparable companies.

Related Party Transactions

• Marlio Charles Mosseri's beneficial ownership is indirect, held through Emerald Hill Ventures SARL SPF, of which Mr. Mosseri is the beneficial owner.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive signal, potentially boosting investor confidence in the company's future.

Next Steps

• The reporting person has undertaken to provide full information regarding the number of shares purchased at each separate price upon request by the SEC staff, the issuer, or a shareholder.

Key Dates

Keywords

Nuvectis Pharma, NVCT, Marlio Charles Mosseri, insider buying, stock purchase, director, 10% owner, Emerald Hill Ventures, SEC Form 4, beneficial ownership, equity